StockData

Charles River Laboratories International vs Medpace

CRL and MEDP side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRL and MEDP compare

Medpace is the larger company, worth 1.2 times as much as Charles River Laboratories International ($18.3B against $15.9B).

Medpace grew revenue faster over the last twelve months (20.4% versus −0.74% for Charles River Laboratories International).

Medpace keeps more of each dollar of sales as profit, with a net margin of 18.2% compared with −6.0% at Charles River Laboratories International.

Medpace scores higher on the StockData Score (14 against 6 for Charles River Laboratories International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRLMEDP
Size and price
Market cap$15.9B$18.3B
Share price$332.16$653.09
Change, 1 year97.9%10.7%
Change, 5 years−11.5%211%
Beta (5Y)1.420.33
Employees20K6,200
StockData Score
Total score614 (better)
Valuation score00
Growth score14 (better)
Performance score25 (better)
Health score35 (better)
Dividend score00
Valuation
P/E–36.2×
P/S4.0× (better)6.4×
P/B5.6× (better)31.2×
EV/EBITDA47.2×28.9× (better)
P/FCF42.8×27.4× (better)
PEG–1.29
FCF yield2.3%3.7% (better)
Fair value$102.19$459.97
Margin of safety−225%−42.0% (better)
Growth
Revenue growth (TTM)−0.74%20.4% (better)
Revenue growth, 5Y average6.5%22.3% (better)
Net income growth (TTM)–19.6%
EPS growth (TTM)–26.1%
EPS growth, 5Y average–31.8%
Profitability
Operating margin2.3%21.4% (better)
Net margin−6.0%18.2% (better)
FCF margin9.3%23.5% (better)
Return on equity−7.7%118% (better)
Return on invested capital1.3%–
Financial health
Debt / equity0.92 (better)0.00
Net debt / EBITDA6.27–
Interest coverage0.8×–
Current ratio1.35 (better)0.83
Altman Z-score2.948.13 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Buyback yield2.0% (better)1.6%
Shareholder yield2.0% (better)1.6%
Ownership
Held by institutions119%88.3%
Held by insiders1.1%20.0%
Insider net buying, 12 months−$52.1M (better)−$262M
Superinvestors holding12 (better)
Short interest, % of float6.3%6.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.